Pricing Log in Create free account
Saturday 17 October 2026 Export VTRS’s income statement to Excel — free account

Viatris Inc.

VTRS Healthcare Drug Manufacturers Specialty & Generic

Viatris Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, down 2.98% from fiscal 2024. In the quarter to June 2026, revenue grew 4.88%, EPS fell 2,464.1%, free cash flow grew 101.1% and total debt fell 18.1%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for five consecutive years.

18.66 0.44 +2.41%
Market cap
$20.9B
P/E
0.0×
Fwd P/E
61.1×
Dividend yield
2.57%
F-score
4/9
Altman Z
0.61
Beneish M
−3.29
Dividend safety
37/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Viatris Inc. (VTRS) EBITDA

Alert me on EBITDA

Viatris Inc.'s EBITDA for fiscal 2025 was $3.1B, unchanged from fiscal 2024. Over the twelve months to 30 June 2026 it was $2.7B. Over the past ten years it has ranged from $2.0B (fiscal 2020) to $4.6B (fiscal 2022); the current reading is higher than 55% of that period. EBITDA has fallen for 3 consecutive fiscal years. Viatris Inc. ranks 4th of 83 Drug Manufacturers Specialty & Generic companies by EBITDA.

EBITDA, annual

Embed this chart

Annual newest first

Period EBITDA Change
FY2025 $3.1B (4.72%)
FY2024 $3.2B (21.10%)
FY2023 $4.1B (11.97%)
FY2022 $4.6B 3.80%
FY2021 $4.5B 123.03%
FY2020 $2.0B (26.67%)
FY2019 $2.7B (9.31%)
FY2018 $3.0B (7.02%)
FY2017 $3.2B 45.94%
FY2016 $2.2B (10.86%)

Quarterly newest first

Period EBITDA Change
Jun 2026 $678.6M 13.78%
Mar 2026 $596.4M 3.88%
Dec 2025 $574.1M (33.81%)
Sep 2025 $867.3M (4.83%)
42 more quarters

Against its own ten years

Low $2.0B High $4.6B
Ten-year median $3.1B
Current reading's percentile 55

EBITDA against peers

Company EBITDA
TAK Takeda Pharmaceutical Co. compare $8.3B
HLN Haleon PLC Sponsored ADR compare $4.3B
ZTS Zoetis Inc. compare $4.0B
VTRS Viatris Inc. $2.7B
TEVA Teva Pharmaceutical Industries Ltd. compare $2.5B
UTHR United Therapeutics Corporation compare $1.5B
NBIX Neurocrine Biosciences, Inc. compare $832.4M
ELAN Elanco Animal Health Incorporated compare $774.0M
RDY Dr. Reddy's Laboratories Ltd compare $596.0M

What EBITDA is

EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.

Reported line item

The full definition of EBITDA →

More on VTRS